Robert E. Miller

Robert E. Miller appears in our data through filings on Sonoma Pharmaceuticals, Inc. shares, published by SEC (Form 4). The record holds 26 filings, for trades running from 10 November 2009 to 13 March 2018.

Every open-market trade on record is a purchase: 24 purchases worth €91k, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 2 share grants. So far in 2018, the count stands at 4 purchases and no sales.

Half of the purchases are above €2,202 and half below. Of 14 purchases, 12 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. For 14 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 14% of cases, with a median move of -2.4%. Past outcomes like these are no guarantee of what comes next.

The newest entry dates from 14 March 2018: an open-market purchase of €3,929, in Sonoma Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.